dbACP: A Comprehensive Database of Anti-Cancer Peptides

9 result(s) have been found!

Accession Name Sequence Source/Organism Mechanism Assay Type Cell Line Cancer Type Activity
dbacp00821 AaeAP1 FLFSLIPSVIAGLVSAIRN Venom, Aeneas fattailed scorpion, Africa Membrane lysis MTT assay NCI-H460 Human lung adenocarcinoma MIC : 10−4 to 10−9 M
dbacp00829 AaeAP2 FLFSLIPSAIAGLVSAIRN Venom, Aeneas fattailed scorpion, Africa Membrane lysis MTT assay NCI-H460 Human lung adenocarcinoma MIC : 10−4 to 10−9 M
dbacp02010 Buforin IIb RAGLQFPVGRLLRRLLRRLLR Histone H2A Inducing mitochondria-dependent apoptosis MTT/MTS assay NCI-H460 Lung cancer IC50 : 12.1 µg/ml
dbacp02068 Buforin Iib RAGLQFPVGRLLRRLLRRLLR Not found Inducing apoptosis MTT/MTS assay NCI-H460 Not specified IC50 : 12.1 µg/ml
dbacp03518 Kassiniatuerin-3 FIQHLIPLIPHAIQGIKDIF Senegal running frog, Africa Membranolytic mechanism MTT assay NCI-H460 Non-small cell Lung cancer IC50 : 1.67 µM
dbacp08352 Seq ID No. 15 from patent ID US202000079827A1 LKKWWKKVKGLLGGLLGKVTSVIK Synthetic Not Available Tetrazolium-based assay NCI-H460 Lung Cancer Cell viability < 25% at 20 μM
dbacp08355 Seq ID No. 16 from patent ID US202000079827A1 LKKWWKKVKGLLGGLLGKVKSVIK Synthetic Not Available Tetrazolium-based assay NCI-H460 Lung Cancer Cell viability > 50% at 20 μM
dbacp08358 Seq ID No. 17 from patent ID US202000079827A1 LKKWWKKVKGLLGGLLGKVKKVIK Synthetic Not Available Tetrazolium-based assay NCI-H460 Lung Cancer Cell viability > 50% at 20 μM
dbacp08362 Seq ID No. 34 from patent ID US202000079827A1 RRWvRRvRRvWRRvvRvvRRWvRR Synthetic Not Available Tetrazolium-based assay NCI-H460 Lung Cancer Cell viability < 25% at 20 μM